{"id":"b3109aeb-ff26-4602-8679-67184d6e13e8","url":"content/b3109aeb-ff26-4602-8679-67184d6e13e8","title":"Monitoring heart function","outline":"/publication/75bfaa02-cc71-4a79-a7dd-dbc47541edea/outline","content":{"mime":"application/xml","data":"<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<!-- content-type_s: --><!-- Generated by cjs2htmlbase.xsl--><div data-ot-plugin=\"com.congility.html\" lang=\"en\" role=\"main\" xmlns:astX=\"http://www.astoriasoftware.com/translation\"><div class=\"topic recommendation commentable-section\" data-annot-id=\"topic.dita_e6cc54d4-e988-4f8a-9419-e6707410a43e\" id=\"topic.dita_e6cc54d4-e988-4f8a-9419-e6707410a43e\"><article aria-labelledby=\"ariaid-title1\" role=\"article\">\n  \n  \n  <div class=\"body recommendation-text\">\n    <p class=\"p\">Assess the function of the person’s heart every 3 months during trastuzumab or trastuzumab emtansine treatment.  </p>\n    <p class=\"p\">Stop the treatment if the LVEF drops by 10 percentage points or more from baseline and to below 50% (for example, from 55% to 45%).   </p>\n    <p class=\"p\">You should only restart trastuzumab or trastuzumab emtansine after reassessing the function of the person’s heart and discussing the possible benefits and risks with them.  </p>\n    <p class=\"p\">Repeat heart function assessments every 6 months after stopping the treatment, until 2 years from the last dose of trastuzumab or trastuzumab emtansine.</p>\n  </div>\n  <nav class=\"related-links\" role=\"navigation\"><div class=\"linklist\"><strong>Other products</strong><br/><ul class=\"linklist\"><li class=\"linklist\"><a class=\"link\" href=\"https://www.nice.org.uk/guidance/ng136\" target=\"_blank\">Hypertension in adults: diagnosis and management (NG136)</a></li></ul></div></nav>\n</article></div></div>"},"metadata":{},"solr":{"custom":{},"doc":{"href_s":"SD00835138","url_s":"content/b3109aeb-ff26-4602-8679-67184d6e13e8","title_s":"Monitoring heart function","nextTopic_s":"b9a2ce79-28eb-433d-85a6-aadb7735a21a","prevTopic_s":"1f11b0db-e73e-4f23-ba32-54f1dba5ca11"},"nice":{"nice_infotype_s":"recommendation","nice_guideline-id_s":"","nice_content-id_s":"","nice_content-type_s":"","nice_condition-disease_s":"BreastCancer","nice_recommendation-strength_s":"strong","nice_change-in-practice_s":"no"}},"contentObject":{"publicationuuid":"75bfaa02-cc71-4a79-a7dd-dbc47541edea","contentuuid":"b3109aeb-ff26-4602-8679-67184d6e13e8","contentjoinuuid":"76082d09-f486-49b2-81f9-1e4b097f8afd","contentjoinuuids":["76082d09-f486-49b2-81f9-1e4b097f8afd","b6411394-b182-48a0-932b-feab3de553ac"],"publicationjoinuuid":"356cbf6a-a380-418a-9856-781ae39f6dca"}}